^
    over2years
    Although a #osimertinib/#bevacizumab combination was marginally effective in most #glioblastoma patients with #EGFR amplification and #EGFRvIII mutation, a subgroup experienced a long-lasting meaningful benefit. @AndresFCardonaZ @ogarrieta https://t.co/UiIgugXEBN (@JNeurooncol)
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR amplification • EGFRvIII mutation
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib)